We have located links that may give you full text access.
Cucurbitacins as Anticancer Agents: A Patent Review.
Recent Patents on Anti-cancer Drug Discovery 2018 November 20
BACKGROUND: Cucurbitacins belong to a group of tetracyclic triterpenoids that display a wide range of biological effects. In the past, numerous cucurbitacins have been isolated from natural sources and many active compounds have been synthesized using the privileged scaffold in order to enhance its anticancer effects.
OBJECTIVE: This review covers patents on the therapeutic effects of natural cucurbitacins and their synthetic analogs published during the past decade. By far, the majority of patents published are related to cancer and structure-activity relationships (SAR) of these compounds are included to lend gravitas to this important class of natural products.
METHODS: The date about the published patents was downloaded via online open access patent databases.
RESULTS: Cucurbitacins display significant anticancer properties, in particular cucurbitacins B and D which possess very potent effects towards number of cancer cells. Numerous cucurbitacins isolated from natural sources have been derivatized through chemical modification at the C2-OH and C25-OH groups. Most importantly, an acyl ester of the C25-OH and, iso-propyl, n-propyl and ethyl ether groups of the C2-OH demonstrated the most increased anticancer activity.
CONCLUSION: The significant anticancer effects of natural and semi-synthetic cucurbitacins put them as new drug candidates. Moreover, cucurbitacins have the capability to form conjugates with other anticancer drugs which will synergistically enhance their anticancer effects. The authors believe that in order to get lead compounds, there should be a greater focus on the synthesis of homodimers, heterdimers, and halo derivatives of cucurbitacins. In the opinion of the authors the analysis of the published patents on the cucurbitacins indicates that these compounds can be developed into a regimen to treat a wide spectrum of cancers.
OBJECTIVE: This review covers patents on the therapeutic effects of natural cucurbitacins and their synthetic analogs published during the past decade. By far, the majority of patents published are related to cancer and structure-activity relationships (SAR) of these compounds are included to lend gravitas to this important class of natural products.
METHODS: The date about the published patents was downloaded via online open access patent databases.
RESULTS: Cucurbitacins display significant anticancer properties, in particular cucurbitacins B and D which possess very potent effects towards number of cancer cells. Numerous cucurbitacins isolated from natural sources have been derivatized through chemical modification at the C2-OH and C25-OH groups. Most importantly, an acyl ester of the C25-OH and, iso-propyl, n-propyl and ethyl ether groups of the C2-OH demonstrated the most increased anticancer activity.
CONCLUSION: The significant anticancer effects of natural and semi-synthetic cucurbitacins put them as new drug candidates. Moreover, cucurbitacins have the capability to form conjugates with other anticancer drugs which will synergistically enhance their anticancer effects. The authors believe that in order to get lead compounds, there should be a greater focus on the synthesis of homodimers, heterdimers, and halo derivatives of cucurbitacins. In the opinion of the authors the analysis of the published patents on the cucurbitacins indicates that these compounds can be developed into a regimen to treat a wide spectrum of cancers.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app